Credit Suisse upgraded Myriad Genetics (NASDAQ: MYGN) from Underperform to Neutral with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Upgrades

Goldman Remains Cautious on Myriad (MYGN) Following Q2 Results; Moves PT to $22February 5, 2014 2:46 PM Ladenburg Thalmann Downgrades Myriad Genetics (MYGN) to NeutralFebruary 5, 2014 8:17 AM JMP Securities Upgrades Myriad Genetics (MYGN) to Market PerformFebruary 5, 2014 6:56 AM Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 20c; Boosts FY14 OutlookFebruary 4, 2014 4:07 PM Myriad Genetics (MYGN) to Acquire Crescendo Bio in $270M DealFebruary 4, 2014 4:04 PM